Casey Butrus, PharmD

Panelists discuss how employers optimize biosimilar uptake through strategic formulary design, financial incentives, and provider education, enabling health care systems to achieve substantial cost savings while maintaining high-quality patient care.

Panelists discuss how biosimilars have significantly reduced health care costs in the US, with health care systems experiencing significant savings across various therapeutic areas. These cost reductions improve treatment affordability and patient access, with potential cumulative savings in 2025.